Basilea Pharmaceutica AG: Conference Call
03 févr. 2005 01h52 HE
|
Basilea Pharmaceutica Ltd
Basel, Switzerland, Feb. 03, 2005 (PRIMEZONE) -- Conference Call, 3rd February 2005, 4 p.m. CET (10 a.m. EST) Basilea Enters a Global Collaboration with Johnson & Johnson on Ceftobiprole.
Dear...
Basilea's Novel Broad-Spectrum Oral and Intravenous Anti-Fungal Moves into Phase II
04 janv. 2005 01h21 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Jan. 4, 2005 (PRIMEZONE) -- Basilea Pharmaceutica AG announces the start of its phase II program for BAL8557 in oesophageal candidiasis. BAL8557 is a novel anti-fungal intended...
U.S. Federal Trade Commission Does Not Oppose a Potential Collaboration Between Basilea and Johnson & Johnson
15 déc. 2004 01h23 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Dec. 15, 2004 (PRIMEZONE) -- The U.S. Federal Trade Commission recently announced that it granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust...
Basilea's First-In-Class Antibiotic Ceftobiprole (BAL5788) Moves into Phase III
04 nov. 2004 01h23 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Nov. 4, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG announces the start of its international phase III program for ceftobiprole (BAL5788), a novel broad spectrum, first-in-class...
Basilea's First-In-Class Antibiotic Ceftobiprole (BAL5788) Unaffected by Resistance and Novel Once-Daily Antifungal (BAL8557) Active Against Resistant Aspergillus
02 nov. 2004 01h22 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Nov. 2, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG presents sixteen posters at the 44th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in...
Basilea's BAL4079 Moves into Phase III
28 oct. 2004 01h21 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Oct. 28, 2004 (PRIMEZONE) -- Basilea announced today the enrolment of the first patients into its phase III program investigating the efficacy and safety of BAL4079 (alitretinoin)...
Basilea Strong Cash Position and Preparation of Phase III Programs in First-Half 2004
25 août 2004 01h38 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Aug. 25, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG reported today its Interim Results for the first-half of 2004 that include funds raised in the company's Initial Public...
Basilea Awarded EU Research Grant to Advance Fight Against Drug Resistance
30 juin 2004 01h24 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, June 30, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG announced today that it will receive funding as part of a European Commission programme for developing novel antibiotics...
Basilea Appoints New Chief Development Officer
21 juin 2004 01h27 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, June 21, 2004 (PRIMEZONE) -- Basilea Pharmaceutica announced today that it has appointed Rienk Pypstra MD as Chief Development Officer.
Dr. Pypstra, who has served as Basilea's...
Additional FDA Fast Track Designation for Basilea's Novel First-In-Class Antibiotic
16 juin 2004 01h31 HE
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, June 16, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG announced today that it received a second fast track designation from the U.S. Food and Drug Administration (FDA) for its...